NASDAQ Healthcare Medical - Devices MXCT

MaxCyte, Inc.

$ 1.21 7.08 %

MaxCyte, Inc. is a global life sciences enterprise focused on the innovation, advancement, and commercialization of next-generation cell therapies. The company offers a suite of advanced electroporation systems, including the ExPERT ATx, a static device for small to medium-scale cell transfection; the ExPERT STx, which uses flow electroporation to support protein production, drug development, and the expression of therapeutic targets for cell-based assays; the ExPERT GTx, another flow electroporation solution designed for large-scale transfection in therapeutic applications; and the ExPERT VLx, catering to very high-volume cell engineering needs. Additionally, MaxCyte provides disposable processing assemblies (PAs) crucial for cell processing and electroporation, alongside essential accessories such as electroporation buffer solutions and specialized software protocols. The company, established in 1998, operates from its headquarters in Rockville, Maryland.

CEO: Maher Masoud - https://maxcyte.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$6 395.87 %

Recommandation

Buy

DCF

$ -2.77

Loading data...

MXCT vs S&P500

Loading data...

No data available.

Quick ratio

11.29

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-3.27

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.37

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-22.03 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-20.82 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

11.15

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.10

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.28

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
1.21 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.43 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.09 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.